GlaxoSmithKline (GSK Quote) said Thursday it would double its annual flu vaccine production by 2008 as it seeks to enter the U.S. market and expand its efforts worldwide.
The announcement was part of a broad review of its vaccine strategy, as GlaxoSmithKline discussed its vaccine plans for the developing world -- including diseases like malaria and dengue fever -- as well as for competing with giant peers such as Sanofi-Aventis (SNY Quote) and Merck(MRK Quote)on multiple disease fronts in the U.S. and Europe.
Much of Thursday's vaccine discussion isn't new, but taken together, the projected launching of five new vaccines in the next five years could add $11 billion to $18 billion in revenue by 2010. And that doesn't count another 15 products in earlier stages of development. "[Our] vaccines business is set for rapid growth," said David Stout, president of pharmaceuticals for the company, which is based in London and Philadelphia. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,328.89 | 1,102.47 | 2,211.69 | 35.46 |
Oil *
73.88
|
|
UP
20.63
|
UP
6.40
|
UP
31.64
|
UP
0.59
|
10 Yr
3.55%
SPDR Gold
108.95
|
|
+0.20%
|
+0.58%
|
+1.45%
|
+1.69%
|
Data delayed 20 minutes |
Connect with TheStreet